<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20130816014371N3</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-12-09</date_registration>
      <primary_sponsor>Tabriz University of Medical Sciences</primary_sponsor>
      <public_title>Effect of combined exercises (stretching, voluntary balance coordination, aerobic, resistance) along with soy milk supplement on performance, trunk -control-movement, daily life activities, electrolyte balance, ischemic lesion volume and cognitive complication in stroke patients.</public_title>
      <acronym></acronym>
      <scientific_title>Effect of combined exercises (stretching, voluntary balance coordination, aerobic, resistance) along with soy milk supplement on performance, trunk -control-movement, daily life activities, electrolyte balance, ischemic lesion volume and cognitive complication in stroke patients.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-12-15</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>120</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/67293</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: The random sequence of allocation by a person not involved in the research using RAS (Random Allocation Software) and random block design using blocks of three and six for allocation in three groups: intervention group 1, intervention group 2 and control (production) will be done. Allocation concealment will be done based on the sequence produced by using opaque, closed and identical envelopes numbered from number 1 to the end. The first person who enters the study will be given envelope number 1 and This process will continue until the end, so the researcher and the researched person will not know the type of Allocation Concealment received until after the envelopes are opened. In this study, the patients will be the ones filling the questionnaire, the statistical analyzer and the outcome examiner will be blinded. Sufficient information about the objectives of the research and its importance is given to the participants and they are assured about the confidentiality of their personal information, Blinding description: In this study, the patients will be the ones filling the questionnaire, the statistical analyzer and the outcome examiner will be blinded. Sufficient information about the objectives of the research and its importance is given to the participants and they are assured about the confidentiality of their personal information.
Patients will not be informed about the type of exercises received, and because their hospital room is separate, they will not imitate each other's movements.</study_design>
      <phase>4</phase>
      <hc_freetext>STROKE.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Training group (receiving combined sports training) [TG],. Intervention 2: Intervention group: Exercise group + supplement (receive combined exercise + soy milk supplement) [TS]. Intervention 3: Intervention group: Supplement group (receiving routine hospital activity + soy milk supplement)[SG]. Intervention 4: Control group: Control (receipt of hospital routine activity).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data is potentially shareable after de-identifying individuals.

When:
The access period starts 6 months after the results are published

To whom:
All researchers

Conditions:
For similar studies to consolidate the results

Where to obtain:
To the responsible person's email

How to obtain:
To the responsible person's email

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>dr. Vahid sarraf</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Golgasht</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5155676934</zip>
        <telephone>+98 41 3334 7054</telephone>
        <email>sarraf@tabrizu.ac.ir</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr.vahid sarraf</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Golgasht</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5155676934</zip>
        <telephone>+98 41 3334 7054</telephone>
        <email>sarraf@tabrizu.ac.ir</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Diagnosis of stroke by physician
consciousness level 14 to 16 based on Four Score
NIHSS score 5-15 (National Institutes of Health Stroke Scale)
no TPA
no aphasia (based on (NIHSS criteria, stable vital signs)
systolic blood pressure above 90 mmHg, heart rate above 40 and oxygen saturation above 94%)
absence of significant fractures and orthopedic defects in organs
absence of acute coronary syndrome
respiratory failure or heart failure based on hospital records
absence of conditions life-threatening such as having cardiac arrhythmia or receiving inotrope drugs (dopamine, dobuitamin)
absence of restriction of movement so that the participant can raise his hand to the table
paresis or unilateral body paralysis
inactive range of motion at least 90 degrees for abduction shoulder and elbow flexion and 30 degrees for the wrist</inclusion_criteria>
      <agemin>25 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Overt heart disease such as heart failure, angina pectoris, myocardial infarction within 120 days prior to the intervention, cardiomyopathy, or severe cardiac arrhythmia
inflammation or infection
muscular dystrophy, myasthenia gravis</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>I69.4</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>I69.4</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Training group (receiving combined sports training) [TG],</i_keyword>
      <i_keyword>Intervention group: Exercise group + supplement (receive combined exercise + soy milk supplement) [TS]</i_keyword>
      <i_keyword>Intervention group: Supplement group (receiving routine hospital activity + soy milk supplement)[SG]</i_keyword>
      <i_keyword>Control group: Control (receipt of hospital routine activity)</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>BALANCE. Timepoint: Before the intervention and 1, 2, 3, 4 weeks after the intervention. Method of measurement: through a questionnaire.</prim_outcome>
      <prim_outcome>MORITCITY AND MOBILBITY. Timepoint: Before the intervention and 1, 2, 3, 4 weeks after the intervention. Method of measurement: through a questionnaire.</prim_outcome>
      <prim_outcome>TRUNK CONTROL. Timepoint: Before the intervention and 1, 2, 3, 4 weeks after the intervention. Method of measurement: through a questionnaire.</prim_outcome>
      <prim_outcome>Ability to perform daily tasks. Timepoint: Before the intervention and 1, 2, 3, 4 weeks after the intervention. Method of measurement: through a questionnaire.</prim_outcome>
      <prim_outcome>Electrolytic changes. Timepoint: Before the intervention and 1, 2, 3, 4 weeks after the intervention. Method of measurement: through blood sample analysis.</prim_outcome>
      <prim_outcome>Ischemic lesion volume and cognitive status. Timepoint: Before the intervention and 1, 2, 3, 4 weeks after the intervention: for the cognitive status and size of the lesion before and after the last intervention. Method of measurement: Through a questionnaire: cognitive status and examination of patients' scans: the size of the lesion.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tabriz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-10-18</approval_date>
        <contact_name>Tabriz university</contact_name>
        <contact_address>Golgasht Street, Imam Reza Hospital Tabriz East Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
